Actuate Therapeutics, Inc. Proceeds from Convertible Debt
Actuate Therapeutics, Inc. (ACTU) reported Proceeds from Convertible Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2026-03-26
- Actuate Therapeutics, Inc. proceeds from convertible debt for the quarter ending 2025-12-31 was $0.00.
- Actuate Therapeutics, Inc. proceeds from convertible debt for the quarter ending 2025-09-30 was $0.00.
- Actuate Therapeutics, Inc. proceeds from convertible debt for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Actuate Therapeutics, Inc. proceeds from convertible debt for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Actuate Therapeutics, Inc. proceeds from convertible debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Actuate Therapeutics, Inc. proceeds from convertible debt for fiscal 2024 was $5.50M.
- Actuate Therapeutics, Inc. proceeds from convertible debt for fiscal 2023 was $0.00.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $0.00 10-K · filed 2026-03-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $0.00 derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $1.00M derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $1.00M derived: sum of 3 quarters · filed 2026-03-26 | $5.50M 10-K · filed 2026-03-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.00M derived: sum of 2 quarters · filed 2025-11-13 | $5.50M 10-Q · filed 2025-11-13 | $5.50M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $5.50M 10-Q · filed 2025-08-14 | $5.50M derived: sum of 3 quarters · filed 2025-08-14 | $5.50M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $4.50M 10-Q · filed 2025-05-15 | $4.50M derived: sum of 2 quarters · filed 2025-05-15 | $4.50M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $0.00 derived: sum of 2 quarters · filed 2025-03-13 | $0.00 10-K · filed 2025-03-13 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |